Incidence of Pulmonary, Cardiovascular, and Renal Complications After COVID-19 Post-Acute Phase A Non-interventional, Prospective, Cross-sectional Study

What this Trial Is About

Researchers are investigating the long-term effects of COVID-19 on lung, heart, and kidney health, focusing on the risk of developing chronic non-communicable diseases (NCDs) following the post-acute phase of COVID-19. This observational study aims to better understand how previous, current, and future variants of SARS-CoV-2 in both vaccinated and unvaccinated individuals affect these organ systems. The study will also explore biomarkers and predictive tools to help manage the risk of these diseases and develop clinical guidelines for prevention and care. The study involves three groups: comparators without a history of acute COVID-19, patients fully recovered from acute COVID-19 without organ dysfunction, and patients who experienced lung, heart, or kidney dysfunction during acute COVID-19. Participants will undergo blood sampling for various tests, including proteomics, transcriptomics, and kidney function markers. They will also complete lung function tests, high-resolution CT scans, heart ultrasounds, a six-minute walk test, and symptom questionnaires to assess organ health. Participants will be followed for up to 48 months, with researchers monitoring the incidence of organ dysfunction and chronic diseases related to the lungs, heart, and kidneys. The study will collect detailed clinical data, perform imaging and laboratory assessments, and record physical function and patient-reported symptoms. This long-term follow-up aims to provide insights into the progression and risk factors of post-COVID complications and help improve patient care and health outcomes.

The Incidence of Pulmonary, Cardiovascular and Renal System Non-communicable Complications Associated With the Post-acute Phase of the Infection by Covid-19